Anti-TNF antibodies, compositions, methods and uses

Details Anti-TNF antibodies, compositions, methods and uses Anti-TNF antibodies, compositions, methods and uses

2008-11-13

2010-10-19

Saoud, Christine J (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S009100, C424S130100, C530S388230, C514S826000

Reexamination Certificate

active

07815909

ABSTRACT:
The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.

REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5075236 (1991-12-01), Yone et al.
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5698419 (1997-12-01), Wolpe et al.
patent: 5700788 (1997-12-01), Mongelli et al.
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5776947 (1998-07-01), Kroemer et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 5993833 (1999-11-01), De Lacharriere et al.
patent: 6015558 (2000-01-01), Hotamisligil et al.
patent: 6172202 (2001-01-01), Marcucci et al.
patent: 6190691 (2001-02-01), Mak
patent: 6194451 (2001-02-01), Alpegiani et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 6790444 (2004-09-01), Le et al.
patent: 6835823 (2004-12-01), Le et al.
patent: 6991791 (2006-01-01), Le et al.
patent: 7070775 (2006-07-01), Le et al.
patent: 7101674 (2006-09-01), Le et al.
patent: 7128907 (2006-10-01), Le et al.
patent: 7192584 (2007-03-01), Le et al.
patent: 668864 (1992-10-01), None
patent: 0212489 (1987-03-01), None
patent: 0218868 (1987-04-01), None
patent: 0260610 (1988-03-01), None
patent: 0350690 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0380068 (1990-08-01), None
patent: 0393438 (1990-10-01), None
patent: 0453898 (1991-10-01), None
patent: 0486526 (1992-05-01), None
patent: 0512528 (1992-11-01), None
patent: 0525570 (1993-02-01), None
patent: 0526905 (1993-02-01), None
patent: 0288 088 (1994-03-01), None
patent: 0585705 (1994-03-01), None
patent: 0610201 (1994-08-01), None
patent: 614984 (1994-09-01), None
patent: 0614984 (1994-09-01), None
patent: 0308378 (1994-11-01), None
patent: 0412486 (1994-11-01), None
patent: 0101681 (1994-12-01), None
patent: 0398327 (1995-03-01), None
patent: 0433900 (1995-09-01), None
patent: 0663836 (1997-07-01), None
patent: 61-047500 (1986-03-01), None
patent: 02-227095 (1990-09-01), None
patent: WO 89/08460 (1989-09-01), None
patent: WO 90/00902 (1990-02-01), None
patent: WO 90/01950 (1990-03-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 91/04054 (1991-04-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/01059 (1992-01-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 94/08609 (1994-04-01), None
patent: WO 94/08619 (1994-04-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 97/29131 (1997-08-01), None
patent: WO 03/083061 (2003-10-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Beutler, B. et al., “Identity of tumour necrosis factor and the macrophage-secreted factor cachectin,”Nature, 316:552-554 (1985).
Beutler, B. et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science, 229:869-871 (1985).
Morrison, Sherie L., “Transfectomas Provide Novel Chimeric Antibodies,”Science, 229:1202-1207 (1985).
Liang, Chi-Ming et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin,”Biochem. & Biophy. Res. Comm., 137(2):847-854 (1986).
Hirai, Makoto et al., “Production and characterization of monoclonal antibodies to human tumor necrosis factor,”J. of Immun. Methods, 96:57- 62 (1987).
Piguet, Pierre-Francois et al., “Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease,”J. Exp. Med., 166:1280-1289 (1987).
Meager, Anthony et al., “Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF),”Hybridoma, 6(3):305-311 (1987).
Fendly, Brian M. et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma, 6(4):359-370.
Bringman, Timothy S. and Aggarwal, Bharat B., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes,” Hybridoma, 6(5):489-507 (1987).
Tracey, Kevin J. et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,”Nature, 330:662-664 (1987).
Nagai, M. et al., “Antibody to tumor necrosis factor (TNF) reduces endotoxin fever,”Experientia, 44:606-607 (1988).
Shimamoto, Yoshinori et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock,”Immunology Letters, 17:311-318 (1988).
Di Giovine, Francesco, S. et al., “Tumour necrosis factor in synovial exudates,”Annals of the Rheumatic Diseases, 47:768-772 (1988).
Collins, M.S. et al., “Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of Pseudomonas aeruginosa,” Abstract E-63,Abstracts of Annual Meeting 1989.
Exley, A.R. et al., “Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys,”Medical Research Society, Abstract 184, p. 50 (1989).
Cross, A.S. et al., “Pretreatment with Recombinant Murine Tumor Necrosis Factor α/Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection,”J. of Exp. Med.,169:2021-2027 (1989).
Engelmann, Hartmut et al., “A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity,”J. of Bio. Chem.,264(20):11974-11980 (1989).
Silva, Ayona T. et al., “Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-60 in Experimental Gram-Negative Shock,”J. of Infectious Diseases, 162:421-427 (1990).
Opal, Steven M. et al., “Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection withPseudomonas aeruginosa,”J. of Infectious Diseases, 161:1148-1152 (1990).
Tavernier, Jan et al., “Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis,”J. Mol. Biol.,211:493-501 (1990).
Lucas, R. et al., “Generation and characterization of a neutralizing rat anti-rm TNF-α monoclonal antibody,”Immunology, 71:218-223 (1990).
Hinshaw, L.B. et al., “Survival of Primates in LD100Septic Shock Following Therapy with Anitbody to Tumor Necrosis Factor (TNFα) , ”Circ

Affiliated with

Also associated with

Rating

Anti-TNF antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-TNF antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TNF antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4237437